Aidoc vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Aidoc is an AI radiology platform with FDA-cleared algorithms that detect and flag critical findings in medical scans, helping radiologists prioritize urgent cases.
About
Aidoc is an Israeli-American AI medical imaging company founded in 2016 that has built a comprehensive AI radiology platform with the largest portfolio of FDA-cleared imaging algorithms in the market. The platform integrates with radiology workflow systems to automatically analyze incoming scans, detect critical findings across multiple conditions, and prioritize worklists so radiologists review the most urgent cases first rather than working strictly in order of arrival. Aidoc's algorithms cover a broad range of conditions across multiple anatomical regions including intracranial hemorrhage, pulmonary embolism, incidental pulmonary nodules, and spine fractures. The company raised over $140M and is deployed at over 1,000 healthcare sites worldwide. Aidoc's aiOS platform enables third-party AI algorithms to run alongside its own models, creating an open ecosystem for AI in radiology. The company serves radiology departments seeking to improve throughput, reduce missed findings, and support radiologists managing increasing imaging volumes. Aidoc positions its platform as an AI operating system for radiology rather than a collection of point solutions, enabling comprehensive AI coverage across an entire radiology practice.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.